Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infanrix hexa primary vaccination in infants born to mothers vaccinated with Boostrix during pregnancy or after delivery
2014-001117-41Phase 4Completed
- Sponsor
- GSK
- Start
- May 2015
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of pertussis filamentous haemagglutinin and acellular pertussis vaccine in diphtheria, Tetanus, pertussis and 3 more (2 arms), sponsored by GSK. Primary endpoint: Immunogenicity with respect to components of DTPa-HBV-IPV/Hib. Started May 2015; status: completed.
02
Drugs
pertussis filamentous haemagglutininacellular pertussis vaccine
03
Conditions
diphtheriaTetanuspertussishepatitis B (HBV)poliomyelitis
Beyond the preview
Go deeper on 2014-001117-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001117-41.